FDA

Health tech Lizzy Lawrence

STAT Plus: Medicare finalizes reimbursement rule for breakthrough medical devices

Health tech Mohana Ravindranath

STAT Plus: FDA’s digital health advisory committee takes shape, and a critique of cost-effectiveness studies

First Opinion Darrell Rigel

Rising rates of skin cancer: The cost of FDA’s inaction on novel sunscreen products

Politics Sarah Owermohle and Rachel Cohrs Zhang

STAT Plus: 7 key people who could shape Trump’s health care policy

The Readout LOUD Elaine Chen, Adam Feuerstein, and Allison DeAngelis

STAT Plus: UnitedHealth’s doctor empire, an FDA departure, and Viking’s obesity moves

First Opinion Thomas R. Insel

Adding psychotherapy to drug therapy works, but the FDA may not be able to handle it

Exclusive Lizzy Lawrence

STAT Plus: Jeff Shuren, medical devices head at FDA, to leave the agency

First Opinion Richard Macary

Fixing the reimbursement and coverage divide between ‘breakthrough’ drugs and medical devices

Politics Olivia Goldhill

STAT Plus: FDA investigators have not spoken with patients and others alleging misconduct in MDMA trials

Politics Nicholas Florko

STAT Plus: ‘Legal’ psychedelic mushrooms actually contain illegal hallucinogens, study shows

Exclusive Nicholas Florko

STAT Plus: Applesauce lead contamination could not have been prevented, top FDA official suggests

The Readout Elaine Chen

STAT Plus: Roche looks to have a competitive GLP-1 drug

The Readout Meghana Keshavan

STAT Plus: What are the odds we get an heir to Paxlovid?

Exclusive Nicholas Florko

STAT Plus: Top FDA officials weighing regulation of ultra-processed foods, internal documents show

The Readout Meghana Keshavan

STAT Plus: Element Biosciences raises another massive round

In the Lab Alia Sajani and Angus Chen

CAR-T cell therapy’s complications, as well as its benefits, become clearer in ‘flurry’ of cancer studies

The Readout Elaine Chen

STAT Plus: Can you get satiety with GLP-1s without the nausea?

The Readout Elaine Chen

STAT Plus: uniQure shares soar on Huntington’s data

The Readout Elaine Chen

STAT Plus: Lilly’s obesity drug looks more potent than Novo’s in observational study

The Readout Meghana Keshavan

STAT Plus: The biotech news you missed this week

First Opinion Lynn Brielmaier

My stalled relay race to get access to ALS drugs in development

Exclusive Brittany Trang and Mohana Ravindranath

STAT Plus: Top Biden administration officials withdraw from Coalition for Health AI

Politics Associated Press

STAT Plus: Supreme Court to weigh whether the FDA was heavy-handed with flavored e-cigarette products

Matt's Take Matthew Herper

STAT Plus: How controversial was the decision by FDA’s Peter Marks to approve Sarepta’s gene therapy? Check its footnotes

Pharma Nicholas Florko, Lizzy Lawrence, John Wilkerson, and Elaine Chen

STAT Plus: Supreme Court’s gutting of Chevron doctrine could mean headaches for drug industry

Letters to the editor Patrick Skerrett

What readers have to say about long Covid, FDA and diversity, and more

Politics Nicholas Florko

STAT Plus: Vape makers see Supreme Court ruling as a weapon in fighting FDA

The Readout Meghana Keshavan

STAT Plus: Will Medicare finally begin covering weight loss drugs like Zepbound and Wegovy?

Politics Olivia Goldhill

STAT Plus: Don’t write off MDMA yet: How the FDA got on board with psychedelics